Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 134241,
    "name": "Jagsonpal Pharma",
    "stock_name": "Jagsonpal Pharma",
    "full_name": "Jagsonpal Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/jagsonpal-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "185.10",
    "chg": 0.75,
    "chgp": "0.41%",
    "dir": 1,
    "prev_price": "184.35",
    "mcapval": "1,237.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 507789,
    "symbol": "JAGSNPHARM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE048B01035",
    "curr_date": "Apr 01",
    "curr_time": "",
    "bse_nse_vol": "1.28 lacs",
    "exc_status": "Active",
    "traded_date": "Apr 01, 2026",
    "traded_date_str": "2026 04 01",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/jagsonpal-pharma-134241-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Jagsonpal Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jagsonpal-pharmaceuticals-ltd-is-rated-sell-3927367",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/JagsonpalPharma_mojoScore_3927367.png",
        "date": "2026-03-31 10:10:13",
        "description": "Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jagsonpal-pharmaceuticals-ltd-is-rated-sell-3902884",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/JagsonpalPharma_mojoScore_3902884.png",
        "date": "2026-03-20 10:10:03",
        "description": "Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Ltd Sees Mixed Technical Signals Amid Price Momentum Shift",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-ltd-sees-mixed-technical-signals-amid-price-momentum-shift-3884227",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/JagsonpalPharma_technicaldot_3884227.png",
        "date": "2026-03-11 08:00:17",
        "description": "Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. Despite a 4.24% gain on the day, the stock’s overall momentum and technical indicators suggest a cautious outlook, with a recent downgrade from Hold to Sell by MarketsMOJO underscoring the evolving market sentiment."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jagsonpal-pharmaceuticals-ltd-is-rated-sell-3879086",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/JagsonpalPharma_mojoScore_3879086.png",
        "date": "2026-03-09 10:10:18",
        "description": "Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jagsonpal-pharmaceuticals-ltd-is-rated-sell-3879070",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/JagsonpalPharma_mojoScore_3879070.png",
        "date": "2026-03-08 10:10:14",
        "description": "Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Ltd Valuation Shifts Signal Growing Price Caution",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-ltd-valuation-shifts-signal-growing-price-caution-3867954",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/JagsonpalPharma_valuationdot_3867954.png",
        "date": "2026-03-04 08:00:07",
        "description": "Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating, reflecting changing market perceptions amid broader sector volatility. Despite robust operational metrics, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a recalibration of price attractiveness relative to peers and historical averages."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jagsonpal-pharmaceuticals-ltd-is-rated-sell-3855267",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/JagsonpalPharma_mojoScore_3855267.png",
        "date": "2026-02-25 10:10:25",
        "description": "Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/jagsonpal-pharmaceuticals-ltd-is-rated-sell-3839144",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/JagsonpalPharma_mojoScore_3839144.png",
        "date": "2026-02-14 10:10:18",
        "description": "Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Jagsonpal Pharmaceuticals Ltd Valuation Shifts Signal Price Attractiveness Change",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/jagsonpal-pharmaceuticals-ltd-valuation-shifts-signal-price-attractiveness-change-3827684",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/JagsonpalPharma_valuationdot_3827684.png",
        "date": "2026-02-09 08:00:13",
        "description": "Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from a very expensive to an expensive rating. This change reflects evolving market perceptions and impacts the stock’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 235,
    "sid": "134241",
    "stock_news_url": "https://www.marketsmojo.com/news/jagsonpal-pharmaceuticals-134241"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "26-Mar-2026",
      "details": "Closure of Trading Window for the quarter and Financial Year Ended on March 31 2026.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "26-Mar-2026",
      "details": "Pursuant to Regulation 30 of SEBI (LODR) Regulations 2015 we hereby submit copy of advertisement published in Newspaper with regard to Postal Ballot Notice sent to the Shareholders of Company.",
      "source": "BSE"
    },
    {
      "caption": "Shareholder Meeting / Postal Ballot-Notice of Postal Ballot",
      "datetime": "25-Mar-2026",
      "details": "Pursuant to Regulation 30 of SEBI (LODR) Regulations 2015 Please find attached Postal ballot Notice relating to approval for Buy back of upto Rs. 1600000 Equity shares of face value Rs. 2 each at a price of Rs. 250/- per share for an aggregate amount not exceeding Rs. 40 crores.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Jagsonpal Pharmaceuticals Ltd has declared <strong>125%</strong> dividend, ex-date: 12 Sep 25",
          "dt": "2025-09-12",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Jagsonpal Pharmaceuticals Ltd has announced <strong>2:5</strong> stock split, ex-date: 08 Jan 25",
          "dt": "2025-01-08",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Jagsonpal Pharmaceuticals Ltd is Rated Sell

2026-03-31 10:10:13

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

Jagsonpal Pharmaceuticals Ltd is Rated Sell

2026-03-20 10:10:03

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Jagsonpal Pharmaceuticals Ltd Sees Mixed Technical Signals Amid Price Momentum Shift

2026-03-11 08:00:17

Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. Despite a 4.24% gain on the day, the stock’s overall momentum and technical indicators suggest a cautious outlook, with a recent downgrade from Hold to Sell by MarketsMOJO underscoring the evolving market sentiment.

Read full news article

Jagsonpal Pharmaceuticals Ltd is Rated Sell

2026-03-09 10:10:18

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Jagsonpal Pharmaceuticals Ltd is Rated Sell

2026-03-08 10:10:14

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Jagsonpal Pharmaceuticals Ltd Valuation Shifts Signal Growing Price Caution

2026-03-04 08:00:07

Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating, reflecting changing market perceptions amid broader sector volatility. Despite robust operational metrics, the stock’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a recalibration of price attractiveness relative to peers and historical averages.

Read full news article

Jagsonpal Pharmaceuticals Ltd is Rated Sell

2026-02-25 10:10:25

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Jagsonpal Pharmaceuticals Ltd is Rated Sell

2026-02-14 10:10:18

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Jagsonpal Pharmaceuticals Ltd Valuation Shifts Signal Price Attractiveness Change

2026-02-09 08:00:13

Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, moving from a very expensive to an expensive rating. This change reflects evolving market perceptions and impacts the stock’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.

Read full news article

View All News